Short answer: IGF-1 LR3 is a powerful experimental analog with almost no clinical evidence supporting the outcomes claimed by peptide vendors
inutile utilizzare un farmaco cos potente e anche cos raro, vista la sua limitata disponibilit soprattutto in Italia, per degli scopi che non hanno niente a che fare con il trattamento di una malattia cronica come lobesit
These variables, which were selected because they are likely to affect treatment outcomes, encompassed both demographic factors (region, sex, age at index date) and clinical history (baseline HbA1c, baseline weight, CVD in the past 365 day [coronary heart disease, cerebrovascular disease, peripheral vascular disease or heart failure], CharlsonDeyo risk index score), as well as index year, insurance type and previous receipt of oral antidiabetic medications
The Wegovy pill is approved for adults (not pediatrics) and comes with highly specific dosing and absorption instructions